Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire
Identifieur interne : 004283 ( Istex/Corpus ); précédent : 004282; suivant : 004284Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire
Auteurs : Mireille Kalou ; Madeleine Sassan-Morokro ; Lucien Abouya ; Célestin Bile ; Chantal Maurice ; Mathieu Maran ; Odette Tossou ; Thierry Roels ; Alan E. Greenberg ; Stefan Z. Wiktor ; John N. NkengasongSource :
- Journal of Medical Virology [ 0146-6615 ] ; 2005-02.
English descriptors
- KwdEn :
- Abidjan, African patients, Becton dickinson, Blood donors, Ccr5, Cote, Cotrimoxazole, Cotrimoxazole group, Cotrimoxazole treatment, Coulibaly, Disease control, Disease progression, Horizontal lines, Human virus, Human virus type, Immune, Immune activation, Immune activation markers, Marker, Median, Median levels, Median plasma, Mycobacterium tuberculosis, Neopterin, Outlier values, Placebo, Placebo group, Plasma samples, Pulmonary tuberculosis, Rank test, Regimen, Standard regimens, Standard treatment, Successful treatment, Treatment regimens, Tuberculosis, Tuberculosis patients, Tuberculosis therapy, Tumor necrosis factor, Viral, Viral load, Virus type, Wilcoxon, Wilcoxon test.
- Teeft :
- Abidjan, African patients, Becton dickinson, Blood donors, Ccr5, Cote, Cotrimoxazole, Cotrimoxazole group, Cotrimoxazole treatment, Coulibaly, Disease control, Disease progression, Horizontal lines, Human virus, Human virus type, Immune, Immune activation, Immune activation markers, Marker, Median, Median levels, Median plasma, Mycobacterium tuberculosis, Neopterin, Outlier values, Placebo, Placebo group, Plasma samples, Pulmonary tuberculosis, Rank test, Regimen, Standard regimens, Standard treatment, Successful treatment, Treatment regimens, Tuberculosis, Tuberculosis patients, Tuberculosis therapy, Tumor necrosis factor, Viral, Viral load, Virus type, Wilcoxon, Wilcoxon test.
Abstract
We analyzed changes in plasma human immunodeficiency virus (HIV)‐1 viral load, CD4+ T‐cell count, and markers of immune activation markers at start of treatment of tuberculosis and 12 months after among 44 HIV‐1‐infected patients with newly diagnosed, sputum‐smear positive for Mycobacterium tuberculosis pulmonary in fection. All patients received a standard regimen of 6 months of rifampicin and isoniazid with first 2 months of pyrazinamid with or without cotrimoxazole. Compared with values at start of treatment, median viral load increased by a median of 0.64 log10 copies/ml after 12 months of follow‐up (P = 0.0002). Median CD4+ T‐cell counts were 393 cells/L at start of treatment and 370 cells/L after 12 months of follow‐up (P = 0.61). Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Levels of viral load, CD4+ T‐cell counts, and markers of immune activation were not different for patients on standard treatment of tuberculosis compared with those on standard and cotrimoxazole treatment. Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Because viral load is a predictor of disease progression, its persistent elevated levels in blood of HIV‐infected patients co‐infected with tuberculosis, who successfully complete TB treatment, may account for the high mortality observed in this population. J. Med. Virol. 75:202–208, 2005. © 2004 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/jmv.20257
Links to Exploration step
ISTEX:CD3FFB24039AD242B4E2D78C2D1D7121FC626D65Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title><author><name sortKey="Kalou, Mireille" sort="Kalou, Mireille" uniqKey="Kalou M" first="Mireille" last="Kalou">Mireille Kalou</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Sassan Orokro, Madeleine" sort="Sassan Orokro, Madeleine" uniqKey="Sassan Orokro M" first="Madeleine" last="Sassan-Morokro">Madeleine Sassan-Morokro</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Abouya, Lucien" sort="Abouya, Lucien" uniqKey="Abouya L" first="Lucien" last="Abouya">Lucien Abouya</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Bile, Celestin" sort="Bile, Celestin" uniqKey="Bile C" first="Célestin" last="Bile">Célestin Bile</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Maurice, Chantal" sort="Maurice, Chantal" uniqKey="Maurice C" first="Chantal" last="Maurice">Chantal Maurice</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Maran, Mathieu" sort="Maran, Mathieu" uniqKey="Maran M" first="Mathieu" last="Maran">Mathieu Maran</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Tossou, Odette" sort="Tossou, Odette" uniqKey="Tossou O" first="Odette" last="Tossou">Odette Tossou</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Roels, Thierry" sort="Roels, Thierry" uniqKey="Roels T" first="Thierry" last="Roels">Thierry Roels</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Global AIDS Program, National Center for STD, HIV, and TB prevention, Centers for Disease Control and Prevention, Atlanta, GA.</mods:affiliation></affiliation></author><author><name sortKey="Greenberg, Alan E" sort="Greenberg, Alan E" uniqKey="Greenberg A" first="Alan E." last="Greenberg">Alan E. Greenberg</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation></author><author><name sortKey="Wiktor, Stefan Z" sort="Wiktor, Stefan Z" uniqKey="Wiktor S" first="Stefan Z." last="Wiktor">Stefan Z. Wiktor</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation></author><author><name sortKey="Nkengasong, John N" sort="Nkengasong, John N" uniqKey="Nkengasong J" first="John N." last="Nkengasong">John N. Nkengasong</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jcn5@cdc.gov</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Division of AIDS/STD/TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA; 1600 Clifton Road (MS A25), Atlanta, GA 30333.===</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CD3FFB24039AD242B4E2D78C2D1D7121FC626D65</idno><date when="2005" year="2005">2005</date><idno type="doi">10.1002/jmv.20257</idno><idno type="url">https://api.istex.fr/document/CD3FFB24039AD242B4E2D78C2D1D7121FC626D65/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">004283</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">004283</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title><author><name sortKey="Kalou, Mireille" sort="Kalou, Mireille" uniqKey="Kalou M" first="Mireille" last="Kalou">Mireille Kalou</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Sassan Orokro, Madeleine" sort="Sassan Orokro, Madeleine" uniqKey="Sassan Orokro M" first="Madeleine" last="Sassan-Morokro">Madeleine Sassan-Morokro</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Abouya, Lucien" sort="Abouya, Lucien" uniqKey="Abouya L" first="Lucien" last="Abouya">Lucien Abouya</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Bile, Celestin" sort="Bile, Celestin" uniqKey="Bile C" first="Célestin" last="Bile">Célestin Bile</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Maurice, Chantal" sort="Maurice, Chantal" uniqKey="Maurice C" first="Chantal" last="Maurice">Chantal Maurice</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Maran, Mathieu" sort="Maran, Mathieu" uniqKey="Maran M" first="Mathieu" last="Maran">Mathieu Maran</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Tossou, Odette" sort="Tossou, Odette" uniqKey="Tossou O" first="Odette" last="Tossou">Odette Tossou</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation></author><author><name sortKey="Roels, Thierry" sort="Roels, Thierry" uniqKey="Roels T" first="Thierry" last="Roels">Thierry Roels</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation><affiliation><mods:affiliation>Current Address: Global AIDS Program, National Center for STD, HIV, and TB prevention, Centers for Disease Control and Prevention, Atlanta, GA.</mods:affiliation></affiliation></author><author><name sortKey="Greenberg, Alan E" sort="Greenberg, Alan E" uniqKey="Greenberg A" first="Alan E." last="Greenberg">Alan E. Greenberg</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation></author><author><name sortKey="Wiktor, Stefan Z" sort="Wiktor, Stefan Z" uniqKey="Wiktor S" first="Stefan Z." last="Wiktor">Stefan Z. Wiktor</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation></author><author><name sortKey="Nkengasong, John N" sort="Nkengasong, John N" uniqKey="Nkengasong J" first="John N." last="Nkengasong">John N. Nkengasong</name><affiliation><mods:affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</mods:affiliation></affiliation><affiliation><mods:affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: jcn5@cdc.gov</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Division of AIDS/STD/TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA; 1600 Clifton Road (MS A25), Atlanta, GA 30333.===</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">75</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="202">202</biblScope><biblScope unit="page" to="208">208</biblScope><biblScope unit="page-count">7</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-02">2005-02</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Abidjan</term><term>African patients</term><term>Becton dickinson</term><term>Blood donors</term><term>Ccr5</term><term>Cote</term><term>Cotrimoxazole</term><term>Cotrimoxazole group</term><term>Cotrimoxazole treatment</term><term>Coulibaly</term><term>Disease control</term><term>Disease progression</term><term>Horizontal lines</term><term>Human virus</term><term>Human virus type</term><term>Immune</term><term>Immune activation</term><term>Immune activation markers</term><term>Marker</term><term>Median</term><term>Median levels</term><term>Median plasma</term><term>Mycobacterium tuberculosis</term><term>Neopterin</term><term>Outlier values</term><term>Placebo</term><term>Placebo group</term><term>Plasma samples</term><term>Pulmonary tuberculosis</term><term>Rank test</term><term>Regimen</term><term>Standard regimens</term><term>Standard treatment</term><term>Successful treatment</term><term>Treatment regimens</term><term>Tuberculosis</term><term>Tuberculosis patients</term><term>Tuberculosis therapy</term><term>Tumor necrosis factor</term><term>Viral</term><term>Viral load</term><term>Virus type</term><term>Wilcoxon</term><term>Wilcoxon test</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Abidjan</term><term>African patients</term><term>Becton dickinson</term><term>Blood donors</term><term>Ccr5</term><term>Cote</term><term>Cotrimoxazole</term><term>Cotrimoxazole group</term><term>Cotrimoxazole treatment</term><term>Coulibaly</term><term>Disease control</term><term>Disease progression</term><term>Horizontal lines</term><term>Human virus</term><term>Human virus type</term><term>Immune</term><term>Immune activation</term><term>Immune activation markers</term><term>Marker</term><term>Median</term><term>Median levels</term><term>Median plasma</term><term>Mycobacterium tuberculosis</term><term>Neopterin</term><term>Outlier values</term><term>Placebo</term><term>Placebo group</term><term>Plasma samples</term><term>Pulmonary tuberculosis</term><term>Rank test</term><term>Regimen</term><term>Standard regimens</term><term>Standard treatment</term><term>Successful treatment</term><term>Treatment regimens</term><term>Tuberculosis</term><term>Tuberculosis patients</term><term>Tuberculosis therapy</term><term>Tumor necrosis factor</term><term>Viral</term><term>Viral load</term><term>Virus type</term><term>Wilcoxon</term><term>Wilcoxon test</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We analyzed changes in plasma human immunodeficiency virus (HIV)‐1 viral load, CD4+ T‐cell count, and markers of immune activation markers at start of treatment of tuberculosis and 12 months after among 44 HIV‐1‐infected patients with newly diagnosed, sputum‐smear positive for Mycobacterium tuberculosis pulmonary in fection. All patients received a standard regimen of 6 months of rifampicin and isoniazid with first 2 months of pyrazinamid with or without cotrimoxazole. Compared with values at start of treatment, median viral load increased by a median of 0.64 log10 copies/ml after 12 months of follow‐up (P = 0.0002). Median CD4+ T‐cell counts were 393 cells/L at start of treatment and 370 cells/L after 12 months of follow‐up (P = 0.61). Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Levels of viral load, CD4+ T‐cell counts, and markers of immune activation were not different for patients on standard treatment of tuberculosis compared with those on standard and cotrimoxazole treatment. Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Because viral load is a predictor of disease progression, its persistent elevated levels in blood of HIV‐infected patients co‐infected with tuberculosis, who successfully complete TB treatment, may account for the high mortality observed in this population. J. Med. Virol. 75:202–208, 2005. © 2004 Wiley‐Liss, Inc.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>viral</json:string><json:string>viral load</json:string><json:string>cotrimoxazole</json:string><json:string>immune</json:string><json:string>immune activation</json:string><json:string>successful treatment</json:string><json:string>wilcoxon</json:string><json:string>standard treatment</json:string><json:string>placebo</json:string><json:string>median</json:string><json:string>immune activation markers</json:string><json:string>abidjan</json:string><json:string>cote</json:string><json:string>cotrimoxazole group</json:string><json:string>ccr5</json:string><json:string>neopterin</json:string><json:string>coulibaly</json:string><json:string>tuberculosis</json:string><json:string>placebo group</json:string><json:string>plasma samples</json:string><json:string>wilcoxon test</json:string><json:string>regimen</json:string><json:string>human virus</json:string><json:string>disease progression</json:string><json:string>tuberculosis patients</json:string><json:string>virus type</json:string><json:string>median plasma</json:string><json:string>standard regimens</json:string><json:string>tumor necrosis factor</json:string><json:string>treatment regimens</json:string><json:string>tuberculosis therapy</json:string><json:string>mycobacterium tuberculosis</json:string><json:string>pulmonary tuberculosis</json:string><json:string>rank test</json:string><json:string>median levels</json:string><json:string>cotrimoxazole treatment</json:string><json:string>human virus type</json:string><json:string>horizontal lines</json:string><json:string>outlier values</json:string><json:string>blood donors</json:string><json:string>african patients</json:string><json:string>disease control</json:string><json:string>becton dickinson</json:string><json:string>marker</json:string></teeft></keywords><author><json:item><name>Mireille Kalou</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Madeleine Sassan‐Morokro</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Lucien Abouya</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Célestin Bile</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Chantal Maurice</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Mathieu Maran</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Odette Tossou</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string></affiliations></json:item><json:item><name>Thierry Roels</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string><json:string>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</json:string><json:string>Current Address: Global AIDS Program, National Center for STD, HIV, and TB prevention, Centers for Disease Control and Prevention, Atlanta, GA.</json:string></affiliations></json:item><json:item><name>Alan E. Greenberg</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string><json:string>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</json:string></affiliations></json:item><json:item><name>Stefan Z. Wiktor</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string><json:string>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</json:string></affiliations></json:item><json:item><name>John N. Nkengasong</name><affiliations><json:string>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</json:string><json:string>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</json:string><json:string>Division of AIDS/STD/TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA; 1600 Clifton Road (MS A25), Atlanta, GA 30333.===</json:string></affiliations></json:item></author><articleId><json:string>JMV20257</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>We analyzed changes in plasma human immunodeficiency virus (HIV)‐1 viral load, CD4+ T‐cell count, and markers of immune activation markers at start of treatment of tuberculosis and 12 months after among 44 HIV‐1‐infected patients with newly diagnosed, sputum‐smear positive for Mycobacterium tuberculosis pulmonary in fection. All patients received a standard regimen of 6 months of rifampicin and isoniazid with first 2 months of pyrazinamid with or without cotrimoxazole. Compared with values at start of treatment, median viral load increased by a median of 0.64 log10 copies/ml after 12 months of follow‐up (P = 0.0002). Median CD4+ T‐cell counts were 393 cells/L at start of treatment and 370 cells/L after 12 months of follow‐up (P = 0.61). Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Levels of viral load, CD4+ T‐cell counts, and markers of immune activation were not different for patients on standard treatment of tuberculosis compared with those on standard and cotrimoxazole treatment. Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Because viral load is a predictor of disease progression, its persistent elevated levels in blood of HIV‐infected patients co‐infected with tuberculosis, who successfully complete TB treatment, may account for the high mortality observed in this population. J. Med. Virol. 75:202–208, 2005. © 2004 Wiley‐Liss, Inc.</abstract><qualityIndicators><score>7.251</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1587</abstractCharCount><pdfWordCount>4455</pdfWordCount><pdfCharCount>27826</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>233</abstractWordCount></qualityIndicators><title>Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title><genre><json:string>article</json:string></genre><host><title>Journal of Medical Virology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1096-9071</json:string></doi><issn><json:string>0146-6615</json:string></issn><eissn><json:string>1096-9071</json:string></eissn><publisherId><json:string>JMV</json:string></publisherId><volume>75</volume><issue>2</issue><pages><first>202</first><last>208</last><total>7</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>virology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>biomedical research</json:string><json:string>virology</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2005</publicationDate><copyrightDate>2005</copyrightDate><doi><json:string>10.1002/jmv.20257</json:string></doi><id>CD3FFB24039AD242B4E2D78C2D1D7121FC626D65</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/CD3FFB24039AD242B4E2D78C2D1D7121FC626D65/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/CD3FFB24039AD242B4E2D78C2D1D7121FC626D65/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/CD3FFB24039AD242B4E2D78C2D1D7121FC626D65/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2004 Wiley‐Liss, Inc.</licence></availability><date type="published" when="2005-02"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main" xml:lang="en">Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title><title level="a" type="short" xml:lang="en">HIV Viral Load and Tuberculosis Therapy</title><author xml:id="author-0000"><persName><forename type="first">Mireille</forename><surname>Kalou</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Madeleine</forename><surname>Sassan‐Morokro</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Lucien</forename><surname>Abouya</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Célestin</forename><surname>Bile</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Chantal</forename><surname>Maurice</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Mathieu</forename><surname>Maran</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Odette</forename><surname>Tossou</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Thierry</forename><surname>Roels</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia<address><country key="US"></country></address></affiliation><affiliation>Current Address: Global AIDS Program, National Center for STD, HIV, and TB prevention, Centers for Disease Control and Prevention, Atlanta, GA.</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Alan E.</forename><surname>Greenberg</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia<address><country key="US"></country></address></affiliation></author><author xml:id="author-0009"><persName><forename type="first">Stefan Z.</forename><surname>Wiktor</surname></persName><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia<address><country key="US"></country></address></affiliation></author><author xml:id="author-0010" role="corresp"><persName><forename type="first">John N.</forename><surname>Nkengasong</surname></persName><email>jcn5@cdc.gov</email><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire<address><country key="CI"></country></address></affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia<address><country key="US"></country></address></affiliation><affiliation>Division of AIDS/STD/TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA; 1600 Clifton Road (MS A25), Atlanta, GA 30333.===</affiliation></author><idno type="istex">CD3FFB24039AD242B4E2D78C2D1D7121FC626D65</idno><idno type="ark">ark:/67375/WNG-99M9NCZK-5</idno><idno type="DOI">10.1002/jmv.20257</idno><idno type="unit">JMV20257</idno><idno type="toTypesetVersion">file:JMV.JMV20257.pdf</idno></analytic><monogr><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="pISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><idno type="book-DOI">10.1002/(ISSN)1096-9071</idno><idno type="book-part-DOI">10.1002/jmv.v75:2</idno><idno type="product">JMV</idno><imprint><biblScope unit="vol">75</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="202">202</biblScope><biblScope unit="page" to="208">208</biblScope><biblScope unit="page-count">7</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2005-02"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p>We analyzed changes in plasma human immunodeficiency virus (HIV)‐1 viral load, CD4+ T‐cell count, and markers of immune activation markers at start of treatment of tuberculosis and 12 months after among 44 HIV‐1‐infected patients with newly diagnosed, sputum‐smear positive for <hi rend="italic">Mycobacterium tuberculosis</hi> pulmonary in fection. All patients received a standard regimen of 6 months of rifampicin and isoniazid with first 2 months of pyrazinamid with or without cotrimoxazole. Compared with values at start of treatment, median viral load increased by a median of 0.64 log<hi rend="subscript">10</hi> copies/ml after 12 months of follow‐up (<hi rend="italic">P</hi> = 0.0002). Median CD4+ T‐cell counts were 393 cells/L at start of treatment and 370 cells/L after 12 months of follow‐up (<hi rend="italic">P</hi> = 0.61). Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Levels of viral load, CD4+ T‐cell counts, and markers of immune activation were not different for patients on standard treatment of tuberculosis compared with those on standard and cotrimoxazole treatment. Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Because viral load is a predictor of disease progression, its persistent elevated levels in blood of HIV‐infected patients co‐infected with tuberculosis, who successfully complete TB treatment, may account for the high mortality observed in this population. J. Med. Virol. 75:202–208, 2005. © 2004 Wiley‐Liss, Inc.</p></abstract><textClass><keywords rend="articleCategory"><term>Research Article</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/CD3FFB24039AD242B4E2D78C2D1D7121FC626D65/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1096-9071</doi><issn type="print">0146-6615</issn><issn type="electronic">1096-9071</issn><idGroup><id type="product" value="JMV"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="JOURNAL OF MEDICAL VIROLOGY">Journal of Medical Virology</title><title type="short">J. Med. Virol.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/jmv.v75:2</doi><numberingGroup><numbering type="journalVolume" number="75">75</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2005-02">February 2005</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="4" status="forIssue"><doi origin="wiley" registered="yes">10.1002/jmv.20257</doi><idGroup><id type="unit" value="JMV20257"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title></titleGroup><copyright ownership="publisher">Copyright © 2004 Wiley‐Liss, Inc.</copyright><eventGroup><event type="manuscriptAccepted" date="2004-09-21"></event><event type="firstOnline" date="2004-12-15"></event><event type="publishedOnlineFinalForm" date="2004-12-15"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-15"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-20"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-30"></event></eventGroup><numberingGroup><numbering type="pageFirst">202</numbering><numbering type="pageLast">208</numbering></numberingGroup><correspondenceTo>Division of AIDS/STD/TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA; 1600 Clifton Road (MS A25), Atlanta, GA 30333.===</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JMV.JMV20257.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="1"></count><count type="referenceTotal" number="32"></count><count type="wordTotal" number="1353"></count></countGroup><titleGroup><title type="main" xml:lang="en">Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title><title type="short" xml:lang="en">HIV Viral Load and Tuberculosis Therapy</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mireille</givenNames><familyName>Kalou</familyName></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Madeleine</givenNames><familyName>Sassan‐Morokro</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Lucien</givenNames><familyName>Abouya</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Célestin</givenNames><familyName>Bile</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Chantal</givenNames><familyName>Maurice</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Mathieu</givenNames><familyName>Maran</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Odette</givenNames><familyName>Tossou</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1 #af2" currentRef="#curr1"><personName><givenNames>Thierry</givenNames><familyName>Roels</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Alan E.</givenNames><familyName>Greenberg</familyName></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Stefan Z.</givenNames><familyName>Wiktor</familyName></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>John N.</givenNames><familyName>Nkengasong</familyName></personName><contactDetails><email>jcn5@cdc.gov</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="CI" type="organization"><unparsedAffiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</unparsedAffiliation></affiliation><affiliation xml:id="curr1"><unparsedAffiliation>Global AIDS Program, National Center for STD, HIV, and TB prevention, Centers for Disease Control and Prevention, Atlanta, GA.</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We analyzed changes in plasma human immunodeficiency virus (HIV)‐1 viral load, CD4+ T‐cell count, and markers of immune activation markers at start of treatment of tuberculosis and 12 months after among 44 HIV‐1‐infected patients with newly diagnosed, sputum‐smear positive for <i>Mycobacterium tuberculosis</i> pulmonary in fection. All patients received a standard regimen of 6 months of rifampicin and isoniazid with first 2 months of pyrazinamid with or without cotrimoxazole. Compared with values at start of treatment, median viral load increased by a median of 0.64 log<sub>10</sub> copies/ml after 12 months of follow‐up (<i>P</i> = 0.0002). Median CD4+ T‐cell counts were 393 cells/L at start of treatment and 370 cells/L after 12 months of follow‐up (<i>P</i> = 0.61). Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Levels of viral load, CD4+ T‐cell counts, and markers of immune activation were not different for patients on standard treatment of tuberculosis compared with those on standard and cotrimoxazole treatment. Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Because viral load is a predictor of disease progression, its persistent elevated levels in blood of HIV‐infected patients co‐infected with tuberculosis, who successfully complete TB treatment, may account for the high mortality observed in this population. J. Med. Virol. 75:202–208, 2005. © 2004 Wiley‐Liss, Inc.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>HIV Viral Load and Tuberculosis Therapy</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire</title></titleInfo><name type="personal"><namePart type="given">Mireille</namePart><namePart type="family">Kalou</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Madeleine</namePart><namePart type="family">Sassan‐Morokro</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Lucien</namePart><namePart type="family">Abouya</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Célestin</namePart><namePart type="family">Bile</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chantal</namePart><namePart type="family">Maurice</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mathieu</namePart><namePart type="family">Maran</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Odette</namePart><namePart type="family">Tossou</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thierry</namePart><namePart type="family">Roels</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</affiliation><affiliation>Current Address: Global AIDS Program, National Center for STD, HIV, and TB prevention, Centers for Disease Control and Prevention, Atlanta, GA.</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alan E.</namePart><namePart type="family">Greenberg</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Stefan Z.</namePart><namePart type="family">Wiktor</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John N.</namePart><namePart type="family">Nkengasong</namePart><affiliation>Projet RETRO‐CI, Abidjan, Côte d'Ivoire</affiliation><affiliation>Division of HIV/AIDS Prevention, National Center for STD, HIV, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia</affiliation><affiliation>E-mail: jcn5@cdc.gov</affiliation><affiliation>Correspondence address: Division of AIDS/STD/TB Laboratory Research, Centers for Disease Control and Prevention, Atlanta, GA; 1600 Clifton Road (MS A25), Atlanta, GA 30333.===</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2005-02</dateIssued><dateValid encoding="w3cdtf">2004-09-21</dateValid><copyrightDate encoding="w3cdtf">2005</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">3</extent><extent unit="tables">1</extent><extent unit="references">32</extent><extent unit="words">1353</extent></physicalDescription><abstract lang="en">We analyzed changes in plasma human immunodeficiency virus (HIV)‐1 viral load, CD4+ T‐cell count, and markers of immune activation markers at start of treatment of tuberculosis and 12 months after among 44 HIV‐1‐infected patients with newly diagnosed, sputum‐smear positive for Mycobacterium tuberculosis pulmonary in fection. All patients received a standard regimen of 6 months of rifampicin and isoniazid with first 2 months of pyrazinamid with or without cotrimoxazole. Compared with values at start of treatment, median viral load increased by a median of 0.64 log10 copies/ml after 12 months of follow‐up (P = 0.0002). Median CD4+ T‐cell counts were 393 cells/L at start of treatment and 370 cells/L after 12 months of follow‐up (P = 0.61). Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Levels of viral load, CD4+ T‐cell counts, and markers of immune activation were not different for patients on standard treatment of tuberculosis compared with those on standard and cotrimoxazole treatment. Levels of serum activation markers decreased significantly at 12 months of follow‐up of the patients for both patients on standard and cotrimoxazole treatment. Because viral load is a predictor of disease progression, its persistent elevated levels in blood of HIV‐infected patients co‐infected with tuberculosis, who successfully complete TB treatment, may account for the high mortality observed in this population. J. Med. Virol. 75:202–208, 2005. © 2004 Wiley‐Liss, Inc.</abstract><relatedItem type="host"><titleInfo><title>Journal of Medical Virology</title></titleInfo><titleInfo type="abbreviated"><title>J. Med. Virol.</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0146-6615</identifier><identifier type="eISSN">1096-9071</identifier><identifier type="DOI">10.1002/(ISSN)1096-9071</identifier><identifier type="PublisherID">JMV</identifier><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>75</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>202</start><end>208</end><total>7</total></extent></part></relatedItem><identifier type="istex">CD3FFB24039AD242B4E2D78C2D1D7121FC626D65</identifier><identifier type="ark">ark:/67375/WNG-99M9NCZK-5</identifier><identifier type="DOI">10.1002/jmv.20257</identifier><identifier type="ArticleID">JMV20257</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Wiley‐Liss, Inc.</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/CD3FFB24039AD242B4E2D78C2D1D7121FC626D65/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004283 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 004283 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:CD3FFB24039AD242B4E2D78C2D1D7121FC626D65
|texte= Changes in HIV RNA viral load, CD4+ T‐cell counts, and levels of immune activation markers associated with anti‐tuberculosis therapy and cotrimoxazole prophylaxis among HIV‐infected tuberculosis patients in Abidjan, Côte d'Ivoire
}}
| This area was generated with Dilib version V0.6.32. |  |